Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. In a new study, researchers Scott Strum, Mark Vincent, Meghan Gipson, Eric McArthur, and Daniel ...
1 One subject in each of the 1, 3, and 6 dose groups relapsed before infusion. 2 From the day of infusion. 3 From the day of radical resection. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results